Abstract
The intersection between regulatory pathways responsive to metabolic fluctuation on one hand, and to cellular stress on the other, is a fascinating area within which NAD/NADH responsive proteins play a major role [1, 2]. A key player amongst these is SIRT1, a member of the mammalian sirtuin family (SIRT1-7). SIRT1 is an NAD-dependent deacetylase with critical functions in the maintenance of homeostasis and cell survival. In this review I shall focus upon (i) the cellular regulation of SIRT1 expression and (ii) the cellular regulation of SIRT1 activity. In addition the distinction between basal and stress-induced functions will be addressed: do they simply reflect a sliding scale of response, or are they mechanistically distinct? Elevated levels of SIRT1 are evident in cancer and SIRT1 can function as a cancer-specific survival factor in human cell lines. However, in a mouse model SIRT1 is reported to function as a tumour suppressor. Possible explanations for this apparent discrepancy will be considered. Given the high profile of SIRT1 as a potential therapeutic target it is clearly important to clarify its basal functioning in relation to differentiation, cell type, intercellular communication, and to age-related disease states including neurodegeneration and cancer.
Current Pharmaceutical Design
Title: Cellular Regulation of SIRT1
Volume: 15 Issue: 1
Author(s): Jo Milner
Affiliation:
Keywords: SIRT1, cancer, regulation, basal, stress, therapy
Abstract: The intersection between regulatory pathways responsive to metabolic fluctuation on one hand, and to cellular stress on the other, is a fascinating area within which NAD/NADH responsive proteins play a major role [1, 2]. A key player amongst these is SIRT1, a member of the mammalian sirtuin family (SIRT1-7). SIRT1 is an NAD-dependent deacetylase with critical functions in the maintenance of homeostasis and cell survival. In this review I shall focus upon (i) the cellular regulation of SIRT1 expression and (ii) the cellular regulation of SIRT1 activity. In addition the distinction between basal and stress-induced functions will be addressed: do they simply reflect a sliding scale of response, or are they mechanistically distinct? Elevated levels of SIRT1 are evident in cancer and SIRT1 can function as a cancer-specific survival factor in human cell lines. However, in a mouse model SIRT1 is reported to function as a tumour suppressor. Possible explanations for this apparent discrepancy will be considered. Given the high profile of SIRT1 as a potential therapeutic target it is clearly important to clarify its basal functioning in relation to differentiation, cell type, intercellular communication, and to age-related disease states including neurodegeneration and cancer.
Export Options
About this article
Cite this article as:
Milner Jo, Cellular Regulation of SIRT1, Current Pharmaceutical Design 2009; 15 (1) . https://dx.doi.org/10.2174/138161209787185841
DOI https://dx.doi.org/10.2174/138161209787185841 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design Evaluation of B Lymphocyte Deficiencies
Cardiovascular & Hematological Disorders-Drug Targets Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology Economic and Cost-Effectiveness Considerations for Pharmacogenetics Tests: An Integral Part of Translational Research and Innovation Uptake in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Generation, Subsets and Functions of Inducible Regulatory T Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bisphosphonates as Treatment of Bone Metastases
Current Pharmaceutical Design Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Current Signal Transduction Therapy The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism Discovery of 8-methoxypyrazino[1,2-a]indole as a New Potent Antiproliferative Agent Against Human Leukemia K562 Cells. A Structure-Activity Relationship Study
Letters in Drug Design & Discovery Meet Our Editor-in-Chief
Clinical Cancer Drugs Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design The Prolyl-Aminodipeptidases and their Inhibitors as Therapeutic Targets for Fibrogenic Disorders
Mini-Reviews in Medicinal Chemistry Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma
Current Drug Targets The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry Strategies for the Design of Non-peptide CCK2 Receptor Agonist and Antagonist Ligands
Current Topics in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation
Current Neuropharmacology